STK38L

Serine/threonine-protein kinase 38-like · Q9Y2H1 · STK38L on Sugi Atlas →

0 patent compounds predicted against STK38L, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to STK38L by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER PHASE2/PHASE3RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations PHASE2COMPLETED
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma PHASE2ACTIVE_NOT_RECRUITING
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON) PHASE1COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors PHASE1RECRUITING
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
New Genes in the Carcinogenesis of Colorectal Cancer nanUNKNOWN
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Exercise in Type 1 Diabetes Mellitus nanCOMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
LRRK2 Activity and Markers of Parkinson's Disease in G2385R Carriers nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Immune Cell Response to Stimuli nanRECRUITING
A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Biomarker Analysis of Gastrointestinal Cancer nanUNKNOWN
Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a STK38L binder may also engage these)

ProteinNameSimilarity
Q7TSE6 1.000 Q7TSE6 →
Q5R8M1 1.000 Q5R8M1 →
A2VDV2 1.000 A2VDV2 →
Q91VJ4 1.000 Q91VJ4 →
STK38 Serine/threonine-protein kinase 38 1.000 landscape →
Q9NBK5 1.000 Q9NBK5 →
Q2LZZ7 1.000 Q2LZZ7 →
O13310 0.997 O13310 →
A8XJL7 0.997 A8XJL7 →
Q2L6W9 0.997 Q2L6W9 →
RPS6KB1 Ribosomal protein S6 kinase beta-1 0.993 landscape →
Q6TJY3 0.993 Q6TJY3 →
STK32A Serine/threonine-protein kinase 32A 0.992 landscape →
Q12706 0.992 Q12706 →
Q8BSK8 0.992 Q8BSK8 →
Q9NAH6 0.992 Q9NAH6 →
Q8BGW6 0.991 Q8BGW6 →
Q54IH8 0.991 Q54IH8 →
Q6TGC6 0.991 Q6TGC6 →
Q9JJX8 0.990 Q9JJX8 →
Q6PFQ0 0.990 Q6PFQ0 →
Q5R4K9 0.990 Q5R4K9 →
A8XJQ6 0.990 A8XJQ6 →
P09215 0.989 P09215 →
Q5R4K3 0.989 Q5R4K3 →
P07934 0.989 P07934 →
Q5RD00 0.989 Q5RD00 →
O19111 0.989 O19111 →
PRKCD Protein kinase C delta type 0.989 landscape →
Q64682 0.988 Q64682 →